SequelSEC

Annovis Bio, Inc. ANVS

Pharmaceutical Preparations · CIK 0001477845 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$29.70M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Annovis Bio, Inc. (ANVS) reported revenue of $0 and net income of -$28.85M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Annovis Bio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Annovis Bio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$29.70M-$26.69M-$45.04M-$25.51M-$14.54M-$6.64M-$1.61M
Net income-$28.85M-$24.59M-$56.20M-$25.33M-$14.49M-$5.46M-$990.98K
Research & development$25.22M$20.00M$38.79M$16.52M$8.48M$3.05M$776.26K
Weighted-average diluted sharesshares 20.55Mshares 12.24Mshares 9.02Mshares 8.16Mshares 7.63Mshares 6.31MUnavailable
Pretax incomeUnavailableUnavailable-$56.20M-$25.33M-$14.49M-$5.46M-$990.98K
Income tax expense$0UnavailableUnavailableUnavailableUnavailableUnavailable$0
Diluted EPS$-1.40$-2.31$-6.23$-3.10$-1.90$-0.87Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$4.48M$6.70M$6.24M$9.00M$6.06M$3.59M$829.37K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Annovis Bio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$19.53M$10.55M$5.75M$28.38M$45.69M$8.07M$1.86K
Total assets$21.08M$13.93M$10.21M$36.02M$46.00M$8.12M$1.12M
Current assetsUnavailableUnavailable$10.21M$36.02M$46.00M$8.12M$747.51K
Total liabilities$4.23M$4.62M$17.96M$7.70M$1.51M$578.38K$2.62M
Current liabilities$3.64M$3.88M$4.28M$7.70M$1.51M$578.38K$2.01M
Total equity incl. NCI$16.85M$9.31M-$7.75M$28.32M$44.49M$7.54M-$8.58M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.59M$2.31M$1.29M$3.96M$688.07K$341.86K$1.23M

Cash flow

Annovis Bio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$25.62M-$21.89M-$39.97M-$17.31M-$9.13M-$3.97M-$476.54K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$34.60M$26.69M$17.34M$4.61K$46.74M$12.04M$443.09K
Net change in cash$8.98M$4.80M-$22.62M-$17.31M$37.61M$8.07M-$33.45K
Stock-based compensation$1.80M$3.84M$4.63M$9.15M$4.70M$1.86M$8.48K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Annovis Bio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratioUnavailableUnavailableUnavailable4.68x30.54x14.04x0.37x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ANVS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-13View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2019-12-31

Difference 7076952 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.